bluuebunny/crossref_metadata_2025_split huggingface dataset:
s-CAPE trauma recovery program: the need for a holistic, trauma- and violence-informed domestic violence framework
Authors: Williams Karen , Harb Merrylord , Satyen Lata , Davies Mia 
Published: November 2024

IntroductionDomestic violence is a worldwide issue of significant concern due to its high global prevalence rates, societal costs, and the pervasive individual-level effects on physical, mental, economic, and social health and functioning. There is therefore an urgent need to deliver effective and consistent recovery services in order to mitigate the harmful societal and individual-level impacts of experiencing domestic violence and to promote victim-survivor recovery and wellbeing. This paper reviews the literature around practice models and frameworks for recovery after domestic violence and proposes the need for a holistic, trauma- and violence-informed approach to facilitate recovery and healing.FindingsResearch indicates that formal supports improve recovery and wellbeing outcomes for victim-survivors, despite some literature gaps. Trauma-and-violence-informed approaches to care and holistic support are proposed as a means of improving recovery services and minimising harm to victim-survivors while maximising wellbeing. However, the literature reveals existing service gaps, including a lack of trauma-informed services and service providers engaging in practices that are retraumatising for victim-survivors.DiscussionThe review findings indicate the lack of a clear and consistent evidence-based recovery framework to provide holistic, trauma-and-violence-informed care that is tailored to the needs of victim-survivors of domestic violence.ConclusionWe present the development of the s-CAPE trauma and recovery program, an integrated, holistic, trauma-and-violence-informed framework for recovery after domestic violence. s-CAPE was developed in Australia's first holistic, women's-only trauma treatment facility and is evidence-based and designed to address current service gaps, promoting positive recovery outcomes for victim-survivors.
Human CD34+-derived plasmacytoid dendritic cells as surrogates for primary pDCs and potential cancer immunotherapy
Authors: Fiore Giovanna , Weckwarth Wolfgang , Paetzold Kerstin , Albertí Servera Llucia , Gies Manuela , Rosenhauer Jakob , Antoniolli Martina , Nassiri Sina , Schmeing Stephan , Dettling Steffen , Soni Bhavesh , Majety Meher , Krug Anne B. , Hoves Sabine , Wolf Monika Julia 
Published: November 2024

IntroductionPlasmacytoid dendritic cells (pDCs) are capable of triggering broad immune responses, yet, their scarcity in blood coupled to their reduced functionality in cancer, makes their therapeutic use for in situ activation or vaccination challenging. MethodsWe designed an in vitro differentiation protocol tailored for human pDCs from cord blood (CB) hematopoietic stem cells (HSCs) with StemRegenin 1 (SR-1) and GM-CSF supplementation. Next, we evaluated the identity and function of CB-pDCs compared to human primary pDCs. Furthermore, we tested the potential of CB-pDCs to support anti-tumor immune responses in co-culture with tumor explants from CRC patients. ResultsHere, we report an in vitro differentiation protocol enabling the generation of 200 pDCs per HSC and highlight the role of GM-CSF and SR-1 in CB-pDC differentiation and function. CB-pDCs exhibited a robust resemblance to primary pDCs phenotypically and functionally. Transcriptomic analysis confirmed strong homology at both, baseline and upon TLR9 or TLR7 stimulation. Further, we could confirm the potential of CB-pDCs to promote inflammation in the tumor microenvironment by eliciting cytokines associated with NK and T cell recruitment and function upon TLR7 stimulation ex vivo in patient tumor explants. DiscussionThis study highlights CB-pDCs as surrogates for primary pDCs to investigate their biology and for their potential use as cell therapy in cancer.
Causal association between plasma metabolites and diverse autoimmune diseases: a two-sample bidirectional mendelian randomization study
Authors: Yuan Xiwen , Yang Peiyan , Hu Jiapeng , Cai Dixin , Hu Baoshan , Rui Gang , Lin Zhiming 
Published: November 2024

BackgroundAutoimmune diseases (ADs) are a category of conditions characterized by misrecognition of autologous tissues and organs by the immune system, leading to severe impairment of patients’ health and quality of life. Increasing evidence suggests a connection between fluctuations in plasma metabolites and ADs. However, the existence of a causal relationship behind these associations remains uncertain.MethodsApplying the two-sample mendelian randomization (MR) method, the reciprocal causality between plasma metabolites and ADs was analyzed. We took the intersection of two metabolite genome-wide association study (GWAS) datasets for GWAS-meta and obtained 1,009 metabolites’ GWAS data using METAL software. We accessed GWAS summary statistics for 5 common ADs, inflammatory bowel disease (IBD), multiple sclerosis (MS), type 1 diabetes (T1D), systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) from published GWAS data. MR analyses were performed in discovery and replication stage simultaneously. Meanwhile, the reverse MR analysis was conducted to investigate the possibility of reverse causal association. Furthermore, a series of sensitivity analyses were conducted to validate the robustness of the results. These statistical analyses were conducted using R software. Finally, the web version of MetaboAnalyst 5.0. was applied to analyze metabolic pathways. Ultimately, we conducted ELISA assays on plasma samples from patients to validate the results.Results4 metabolites were identified to have causal relationships with IBD, 2 metabolites with MS, 13 metabolites with RA, and 4 metabolites with T1D. In the reverse MR analysis, we recognized causality between SLE and 22 metabolites, IBD and 4 metabolites, RA and 22 metabolites, and T1D and 37 metabolites. Additionally, 4 significant metabolic pathways were identified in RA by metabolic pathway analysis in the forward MR analysis. Correspondingly, in the reverse, 11 significant metabolic pathways in RA, 8 in SLE, and 4 in T1D were obtained using identical approaches. Furthermore, the protective role of glutamate was confirmed through ELISA assays.ConclusionsOur research established a reciprocal causality between plasma metabolites and ADs. Furthermore, diverse metabolic pathways correlated with ADs were uncovered. Novel insights into the prediction and diagnosis were provided, as well as new targets for precise treatment of these conditions were discovered.
Depicting the cellular complexity of pancreatic adenocarcinoma by Imaging Mass Cytometry: focus on cancer-associated fibroblasts
Authors: Erreni Marco , Fumagalli Maria Rita , D’Anna Raffaella , Sollai Mauro , Bozzarelli Silvia , Nappo Gennaro , Zanini Damiano , Parente Raffaella , Garlanda Cecilia , Rimassa Lorenza , Terracciano Luigi Maria , Biswas Subhra K. , Zerbi Alessandro , Mantovani Alberto , Doni Andrea 
Published: November 2024

IntroductionPancreatic ductal adenocarcinoma (PDAC) represents the complexity of interaction between cancer and cells of the tumor microenvironment (TME). Immune cells affect tumor cell behavior, thus driving cancer progression. Cancer-associated fibroblasts (CAFs) are responsible of the desmoplastic and fibrotic reaction by regulating deposition and remodeling of extracellular matrix (ECM). As tumor-promoting cells abundant in PDAC ECM, CAFs represent promising targets for novel anticancer interventions. However, relevant clinical trials are hampered by the lack of specific markers and elusive differences among CAF subtypes. Indeed, while single-cell transcriptomic analyses have provided important information on the cellular constituents of PDACs and related molecular pathways, studies based on the identification of protein markers in tissues aimed at identifying CAF subtypes and new molecular targets result incomplete.MethodsHerein, we applied multiplexed Imaging Mass Cytometry (IMC) at single-cell resolution on 8 human PDAC tissues to depict the PDAC composing cells, and profiling immune cells, endothelial cells (ECs), as well as endocrine cells and tumor cells.ResultsWe focused on CAFs by characterizing up to 19 clusters distinguished by phenotype, spatiality, and interaction with immune and tumor cells. We report evidence that specific subtypes of CAFs (CAFs 10 and 11) predominantly are enriched at the tumor-stroma interface and closely associated with tumor cells. CAFs expressing different combinations of FAP, podoplanin and cadherin-11, were associated with a higher level of CA19-9. Moreover, we identified specific subsets of FAP+ and podoplanin+/cadherin-11+ CAFs enriched in patients with negative prognosis.DiscussionThe present study provides new general insights into the complexity of the PDAC microenvironment by defining phenotypic heterogeneities and spatial distributions of CAFs, thus suggesting different functions of their subtypes in the PDAC microenvironment.
Impact of bone metastasis on prognosis in non-small cell lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
Authors: Zhu Yonghua , She Jingyao , Sun Rong , Yan XinXin , Huang Xinyao , Wang Peijuan , Li Bo , Sun Xiangdong , Wang Changqing , Jiang Kai 
Published: November 2024

BackgroundLung cancer is a leading cause of cancer-related deaths globally, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of cases. While immune checkpoint inhibitors (ICIs) have transformed treatment for advanced NSCLC, the role of bone metastasis in modulating ICI efficacy remains unclear. Bone metastasis, occurring in 30-40% of advanced NSCLC cases, is associated with worse outcomes. However, how this affects the therapeutic benefit of ICIs has not been fully elucidated, highlighting a critical knowledge gap in optimizing treatment for this patient population.MethodsA comprehensive literature search across multiple databases, including PubMed, Embase, and Cochrane, identified 13 studies with a total of 3,681 patients, of whom 37.6% had bone metastasis. Overall survival (OS) and progression-free survival (PFS) were compared between NSCLC patients with and without bone metastasis. Data were analyzed using a random-effects model to account for study heterogeneity.ResultsThe meta-analysis demonstrated that bone metastasis significantly worsened overall survival (OS) and progression-free survival (PFS) in NSCLC patients treated with ICIs. Specifically, bone metastasis was associated with a 45% increased risk of death (HR: 1.45, 95% CI: 1.30–1.62, p &lt; 0.001) and a 40% increased risk of disease progression (HR: 1.40, 95% CI: 1.25–1.58, p &lt; 0.001). No statistically significant impact on PFS was observed. (HR: 1.28, 95% CI: 0.77–2.10, p = 0.34). High heterogeneity was observed in some subgroup analyses (I² = 72%), indicating variability in the results.ConclusionBone metastasis is a significant negative prognostic factor for NSCLC patients treated with ICIs, associated with a higher risk of mortality and disease progression. These results underscore the importance of tailored treatment approaches for NSCLC patients with bone metastasis and call for further research to optimize therapy outcomes in this group.
Banxia-Yiyiren alleviates insomnia and anxiety by regulating the gut microbiota and metabolites of PCPA-induced insomnia model rats
Authors: Wang Liang , Qi Xiaorong , Wang Shuo , Tian Chujiao , Zou Tao , Liu Zihan , Chen Qi , Chen Yingfan , Zhao Yunshan , Li Shaodan , Yang Minghui , Chai Ningli 
Published: November 2024

ObjectiveThis study aims to clearly define the effects of Banxia-Yiyiren on the gut microbiota and its metabolites in a para-chlorophenylalanine-induced insomnia model and the possible underlying mechanisms involved.Materials and methodsWe employed 16S ribosomal ribonucleic acid (rRNA) gene sequencing combined with metabonomic analysis to explore the mutual effects of the PCPA-induced insomnia model and the gut microbiota and the intrinsic regulatory mechanism of Banxia-Yiyiren on the gut microbiota and metabolites in the PCPA-induced insomnia model.ResultsBanxia-Yiyiren was identified by mass spectrometry to include amino acids, small peptides, nucleotides, organic acids, flavonoids, fatty acids, lipids, and other main compound components. The elevated plus maze (EPM) test results revealed that high-dose Banxia-Yiyiren may increase willingness to explore by improving anxiety-like symptoms caused by insomnia. Through 16S rRNA gene sequencing, at the phylum level, compared with those in G1, the relative abundances of Bacteroidota and Proteobacteria in G2 increased, whereas the relative abundance of Firmicutes decreased. At the genus level, compared with those in G1, the relative abundances of Prevotella_9, Prevotella, Ralstonia, Escherichia-Shigella, and UCG-005 in G2 increased, whereas the relative abundances of Lactobacillus, Ligilactobacillus, Alloprevotella, Blautia, and Prevotellaceae_NK3B31_group decreased. The metabolomics analysis results revealed 1,574 metabolites, 36.48% of which were classified as lipids and lipid-like molecules, 20.76% as organic acids and their derivatives, and 13.36% as organic heterocyclic compounds. The correlation between the top 20 differentially abundant metabolites in the G1–G2 groups was greater than that between the G3–G2 and G6–G2 groups. Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis revealed that the main differentially abundant metabolites in each group were significantly enriched in various pathways, such as amino acid metabolism, adenosine triphosphate (ATP)-binding cassette (ABC) transporters, protein digestion, and absorption. Additionally, there was a significant Pearson correlation between the genus-level differences in the gut microbiota and the differentially abundant metabolites among the G1–G2, G3–G2, and G6–G2 groups.ConclusionThis study preliminarily verified that the PCPA-induced insomnia model is closely related to gut microbial metabolism and microecological disorders, and for the first time, we confirmed that Banxia-Yiyiren can act on the gut microbiota of PCPA-induced insomnia model rats and alleviate insomnia and anxiety by regulating the species, structure, abundance, and metabolites of the gut microbiota.
Plasma symmetric dimethylarginine as a metabolite biomarker of severe acute ischemic stroke
Authors: Pihlasviita Saana , Mattila Olli S. , Nukarinen Tiina , Kuisma Markku , Harve-Rytsälä Heini , Ritvonen Juhani , Sibolt Gerli , Curtze Sami , Strbian Daniel , Pystynen Mikko , Tatlisumak Turgut , Lindsberg Perttu J. 
Published: November 2024

IntroductionAfter severe ischemic stroke (IS), circulating levels of symmetric dimethylarginine (SDMA) increase. We investigated the early dynamics of SDMA in stroke to potentially aid with prehospital identification of severe IS from hemorrhagic stroke (HS).MethodsWe performed targeted mass spectrometry (MS) measurements of SDMA in two sequential acute plasma samples (early and secondary) of 50 IS patients with LVO and 49 HS patients. Secondary samples of 227 IS and 84 HS patients with moderate to severe symptoms (NIHSS ≥ 7) subsequently underwent ELISA validation.ResultsThe median (IQR) last-known-well (LKW) to sampling times were 43 min (35–67) for early samples in the MS analysis, and 83 min (65–113) for secondary samples in MS and ELISA analyses. No inter-group differences existed in early samples, but IS patients had significantly higher mean (IQR) SDMA levels in secondary samples in both analyses: 5.8 (5.3–6.9) vs. 5.1 (4.2–5.8) A.U. for HS, p &lt; 0.001, with MS; and 0.82 (0.72–1.01) vs. 0.71 (0.58–0.85) nmol/mL for HS, p &lt; 0.001, with ELISA. For IS patients, higher SDMA levels were associated with cardioembolic stroke: 0.84 (0.73–1.09) vs. 0.79 (0.71–0.91) nmol/mL for other etiologies, p = 0.042, and poor outcome: modified Rankin Scale (mRS) 4–6; 0.90 (0.73–1.06) vs. 0.80 (0.72–0.97) nmol/mL for mRS 0–3 (p = 0.045).ConclusionIn a large clinical cohort of stroke patients with moderate to severe symptoms, our data suggest that SDMA can assist in differentiation of IS and HS patients already 1 h and a half after symptom onset. SDMA may prove to have future value in a diagnostic stroke biomarker panel.
Functional brain controllability in Parkinson’s disease and its association with motor outcomes after deep brain stimulation
Authors: Li Ziyu , Liu Zhiqin , Gao Yuan , Tang Biqiu , Gu Shi , Luo Chunyan , Lui Su 
Published: November 2024

IntroductionConsidering the high economic burden and risks of deep brain stimulation (DBS) surgical failure, predicting the motor outcomes of DBS in Parkinson’s disease (PD) is of significant importance in clinical decision-making. Functional controllability provides a rationale for combining the abnormal connections of the cortico-striato-thalamic-cortical (CSTC) motor loops and dynamic changes after medication in DBS outcome prediction.MethodsIn this study, we analyzed the association between preoperative delta functional controllability after medication within CSTC loops and motor outcomes of subthalamic nucleus DBS (STN-DBS) and globus pallidus interna DBS (GPi-DBS) and predicted motor outcomes in a Support Vector Regression (SVR) model using the delta controllability of focal regions.ResultsWhile the STN-DBS motor outcomes were associated with the delta functional controllability of the thalamus, the GPi-DBS motor outcomes were related to the delta functional controllability of the caudate nucleus and postcentral gyrus. In the SVR model, the predicted and actual motor outcomes were positively correlated, with p = 0.020 and R = 0.514 in the STN-DBS group, and p = 0.011 and R = 0.705 in the GPi- DBS group.DiscussionOur findings indicate that different focal regions within the CSTC motor loops are involved in STN-DBS and GPi-DBS and support the feasibility of functional controllability in predicting DBS motor outcomes for PD in clinical decision-making.
Comparative impact of the affordable care act on breast cancer outcomes among women in two US states
Authors: Akinyemi Oluwasegun , Fasokun Mojisola , Weldeslase Terhas , Odusanya Eunice , Akinyemi Irene , Geter Kailyn , Akula Meghana , Michael Miriam , Hughes Kakra , Williams Robin 
Published: November 2024

IntroductionSince the implementation of the Patient Protection and Affordable Care Act (ACA) and Medicaid expansion, states that adopted the policy have seen reduced uninsured rates. However, it is unclear whether increased healthcare access, particularly for minority and socioeconomically disadvantaged groups, has translated into measurable improvements in health outcomes.ObjectiveOur study aims to evaluate the impact of the ACA and Medicaid expansion on breast cancer outcomes in Louisiana, which has implemented the policy, compared to Georgia, which has not, as of 2024.MethodologyWe conducted a retrospective study using SEER registry data from January 2011 to December 2021, including women aged 18-64 diagnosed with breast cancer. The impact of the ACA and Medicaid expansion on cancer-specific survival (CSS), overall survival (OS), and stage at presentation was evaluated. The cohort was divided into pre-ACA (2011-2015) and post-ACA (2017-2021) periods, with a one-year washout (2016). A difference-in-difference (DID) approach compared outcomes between Louisiana and Georgia.ResultsThe study analyzed 62,381 women with breast cancer, with 32,220 cases in the pre-ACA period (51.7%) and 30,161 in the post-ACA period (48.3%). In Georgia, 43,279 women were included (52.3% pre-ACA vs. 47.7% post-ACA), while Louisiana had 19,102 women (50.1% pre-ACA vs. 49.9% post-ACA). Medicaid expansion in Louisiana was associated with a 0.26 percentage point reduction in overall deaths (95% CI: -10.9 to 10.4) and a 5.97 percentage point reduction in cancer-specific mortality (95% CI: -26.1 to 14.2). There was also no significant difference in disease stage at presentation compared to Georgia.ConclusionThis study found no significant differences in overall mortality, cancer-specific mortality, or disease stage at presentation among women with breast cancer in Louisiana, which implemented Medicaid expansion in 2016, compared to Georgia, which has not expanded Medicaid.
Characteristics of voriconazole-induced visual disturbances and hallucinations: case reports and literature review
Authors: Liu Ya , Huang Ying , Liu Xiang , Wang Danxia , Hu Yixiang 
Published: November 2024

Voriconazole, a broad-spectrum antifungal agent, is considered the first-line treatment for invasive aspergillosis. In this article, we report three cases of patients who experienced visual disturbances and hallucinations following voriconazole therapy for invasive pulmonary aspergillosis. These symptoms appeared within 1 week after initiating voriconazole administration and resolved upon discontinuation or dose reduction of the drug. Considering the absence of any identifiable alternative cause and the temporal relationship with voriconazole initiation, these symptoms were attributed to the adverse effects of voriconazole. All three patients had trough concentrations exceeding 5 μg/mL at the time of adverse reactions, leading to subsequent therapeutic drug monitoring and dose adjustment. The clinical characteristics and management strategies of voriconazole-induced hallucinations and/or visual disturbances have been rarely reported previously. Therefore, our study reviewed and analyzed relevant case reports since 2014. This study highlights the importance of recognizing the potential risk of hallucinations and visual disturbances associated with voriconazole. Furthermore, our findings indicate that the route of voriconazole administration does not influence the frequency of these adverse events. Additionally, special attention should be given to monitoring adverse events related to voriconazole in Asian populations due to their higher prevalence of CYP2C19 poor metabolizers. In the event of adverse reactions to voriconazole, diligent monitoring of therapeutic drug levels and dosage adjustments is crucial. These clinical characteristics and management strategies offer advantages in terms of enhancing drug efficacy, ensuring treatment continuity, and minimizing the incidence of other severe adverse reactions.